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Defects of mitochondrial dynamics are emerging causes of neurological disease. In two children presenting with severe neurological
deterioration following viral infection we identiﬁed a novel homozygous STAT2 mutation, c.1836C4A (p.Cys612Ter), using
whole exome sequencing. In muscle and ﬁbroblasts from these patients, and a third unrelated STAT2-deﬁcient patient, we
observed extremely elongated mitochondria. Western blot analysis revealed absence of the STAT2 protein and that the mitochon-
drial ﬁssion protein DRP1 (encoded by DNM1L) is inactive, as shown by its phosphorylation state. All three patients harboured
decreased levels of DRP1 phosphorylated at serine residue 616 (P-DRP1
S616), a post-translational modiﬁcation known to activate
DRP1, and increased levels of DRP1 phosphorylated at serine 637 (P-DRP1
S637), associated with the inactive state of the DRP1
GTPase. Knockdown of STAT2 in SHSY5Y cells recapitulated the ﬁssion defect, with elongated mitochondria and decreased P-
DRP1
S616 levels. Furthermore the mitochondrial ﬁssion defect in patient ﬁbroblasts was rescued following lentiviral transduction
with wild-type STAT2 in all three patients, with normalization of mitochondrial length and increased P-DRP1
S616 levels. Taken
together, these ﬁndings implicate STAT2 as a novel regulator of DRP1 phosphorylation at serine 616, and thus of mitochondrial
ﬁssion, and suggest that there are interactions between immunity and mitochondria. This is the ﬁrst study to link the innate
immune system to mitochondrial dynamics and morphology. We hypothesize that variability in JAK-STAT signalling may con-
tribute to the phenotypic heterogeneity of mitochondrial disease, and may explain why some patients with underlying mitochon-
drial disease decompensate after seemingly trivial viral infections. Modulating JAK-STAT activity may represent a novel
therapeutic avenue for mitochondrial diseases, which remain largely untreatable. This may also be relevant for more common
neurodegenerative diseases, including Alzheimer’s, Huntington’s and Parkinson’s diseases, in which abnormalities of mitochondrial
morphology have been implicated in disease pathogenesis.
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Introduction
Mitochondrial diseases are clinically, biochemically and
genetically heterogeneous disorders characterized by
dysfunction of mitochondria, which are highly dynamic or-
ganelles with multitudinous functions including energy
generation by oxidative phosphorylation (OXPHOS).
Although the dynamic nature of mitochondria was
recognized nearly 100 years ago, only recently have the
processes determining mitochondrial morphology been
unravelled (Lewis and Lewis, 1914; Archer, 2013).
Mitochondrial networks are deﬁned by a delicate balance
of fusion and ﬁssion events that link mitochondrial biogen-
esis to mitophagy, a quality control process for removing
dysfunctional mitochondria in the mitochondrial ‘life cycle’.
When this balance is perturbed, mitochondrial disease
ensues (Table 1)( Chan, 2006; Youle and van der Bliek,
2012).
Several factors necessary for mitochondrial fusion and ﬁs-
sion have been identiﬁed (Archer, 2013). Mitochondrial
fusion is mediated by several large membrane guanosine
triphosphatases (GTPases): the mitofusins (MFN1 and
MFN2) on the outer membrane, and optic atrophy 1
(OPA1) on the inner membrane. Factors involved in ﬁssion
include dynamin related protein 1 (DRP1, encoded by
DNM1L), receptor proteins MiD49 (MIEF2) and MiD51
(MIEF1), mitochondrial ﬁssion protein 1 (FIS1) and mito-
chondrial ﬁssion factor (MFF)( Palmer et al., 2011; Loso ´n
et al., 2013). However, the exact processes coordinating
ﬁssion and fusion remain unknown.
Previously mutations in the ﬁssion factors DRP1 and
MFF have been implicated in causing human mitochondrial
ﬁssion defects (Waterham et al., 2007; Shamseldin et al.,
2012). We have now used whole exome sequencing to
identify mutations in STAT2, encoding a component of
the JAK (janus kinase)-STAT (signal transduction and acti-
vation of transcription) cytokine signalling pathway (Steen
and Gamero, 2013), as a novel cause of disrupted mito-
chondrial ﬁssion in three patients from two unrelated pedi-
grees. These data are the ﬁrst to implicate signalling
pathways of the innate immune system in the regulation
of mitochondrial dynamics.
Materials and methods
Patients
Patient 1 is the elder child of non-consanguineous Albanian
parents. He was well and developing normally until 12
months of age when he developed a febrile illness 1 week
after mumps, measles and rubella (MMR) vaccination unre-
sponsive to antibiotics. CSF cell count was normal. Pyrexia,
lethargy, conjunctivitis, inﬂamed throat and lymphadenopathy
continued, leading to a diagnosis of atypical Kawasaki disease,
treated with intravenous immunoglobulin. Measles serology
prior to immunoglobulin administration was consistent with
recent MMR vaccination. C-reactive protein (CRP) was ini-
tially raised but rapidly fell to normal levels.
One month later, he was readmitted with opsoclonus-
myoclonus. EEG and brain MRI were normal, but repeat
CSF examination revealed 12  10
6/l lymphocytes and low
glucose, with negative bacterial cultures and viral PCRs. He
was treated empirically with intravenous acyclovir and ster-
oids, and improved. Immunology investigations demonstrated
low CD4-positive T cells. Major Histocompatibility Complex
II deﬁciency and HIV were excluded, and proliferative re-
sponse to phytohaemagglutinin was normal. He remained
well until 2.5 years when he presented with fever, diarrhoea,
hypoglycaemia, impaired renal and liver function, metabolic
acidosis (pH 7.15), hyperammonaemia, markedly elevated
CRP and thrombocytopaenia (Supplementary Table 1). He
then developed opsoclonus-myoclonus and seizures, with neu-
roimaging suggestive of meningoencephalitis. He received
treatment with antimicrobials, antifungals and steroids.
Seizures were very difﬁcult to control, and he developed sig-
niﬁcant neurological impairment including four-limb spasticity,
chorea and severe cortical visual impairment, which has not
recovered. He remains on triple anticonvulsant therapy, re-
placement immunoglobulin and antibiotic prophylaxis.
Patient 2, the younger sister of Patient 1, was well until aged
13 months when she developed a febrile illness 1 week after
MMR vaccine. She was anaemic and lymphopaenic with
deranged clotting. CSF was normal except for a positive
PCR for mumps virus. Throat swab PCR was positive for
measles, mumps and rubella. She had detectable antibodies
to all three viruses, suggesting an appropriate immunological
response to the vaccine (Supplementary Table 1). She was
treated with intravenous acyclovir, and was readmitted aged
15 months with persistent fever and malaise. She developed
septic shock with metabolic acidosis requiring intensive care.
2 | BRAIN 2015: Page 2 of 13 R. Shahni et al.
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 CSF culture and PCR for herpes simplex virus (HSV), varicella
zoster virus (VZV) and enterovirus were negative. She was
treated with intravenous ceftriaxone, clindamycin and acyclo-
vir. Her blood counts normalized, and bone marrow aspirate
and lymph node biopsy showed no haemophagocytic lympho-
histiocytosis. Autoantibodies were negative. She made a slow
recovery with no neurological or other deﬁcit, and has re-
mained well other than a diarrhoeal illness, during which im-
munological testing revealed marked lymphopaenia with low B
and T cells. Over the next 12 months her lymphocyte count
and T and B cell numbers normalized. Due to the apparent
association with infection, she remains on replacement im-
munoglobulin. In addition to neurological and immune dys-
function, both children had evidence of mild renal
tubulopathy. Detailed clinical data are provided in
Supplementary Table 1.
Patient 3 (Hambleton et al., 2013), from an unrelated
family, was reported previously to have experienced a pro-
longed febrile illness with multisystem involvement following
MMR. Her affected cousin developed a sterile encephalitic ill-
ness following the same vaccine (Hambleton et al., 2013).
Histological analysis of
mitochondrial morphology in skeletal
muscle and ﬁbroblasts
Electron microscopy
Open skeletal muscle and skin biopsies were performed after
informed parental consent. For ultrastructural examination of
skeletal muscle and cultured skin ﬁbroblasts, samples were
ﬁxed in 2.5% glutaraldehyde buffered with 0.1M sodium
cacodylate (pH 7.2), postﬁxed in 1% osmium tetroxide,
dehydrated in ascending grades of alcohol, processed through
propylene oxide and embedded in Epon
TM
resin. Ultrathin
sections were cut with a diamond knife on a Leica
Ultracut UCT Ultramicrotome, placed on copper grids and
stained with uranyl acetate and lead citrate. Examination
was carried out with a JEOL 1400 transmission electron
microscope.
Live cell imaging
Live cell imaging using confocal microscopy was used to visu-
alize tetramethyl rhodamine methyl ester (TMRM)-labelled
mitochondria in ﬁbroblasts. Primary skin ﬁbroblasts cultured
under standard conditions as described previously (Fassone
et al., 2010) were labelled with 25nM TMRM (Invitrogen)
prior to visualizing mitochondria with the use of a Zeiss
LSM 700 63 oil immersion objective. Identical detector/
gain settings were used for all samples. To determine mem-
brane potential, mean ﬂuorescence intensity (background cor-
rected) of TMRM-labelled mitochondria was analysed using
ImageJ (n=3; 427 cells analysed for each n).
Genetic analyses
Mitochondrial DNA analysis
The whole mitochondrial genome was sequenced in muscle
from Patient 1 using Sanger sequencing, and mtDNA copy
number per diploid nuclear genome was determined in patient
and control ﬁbroblasts by Droplet Digital
TM
PCR (Bio-Rad).
The primers and probes used in this study have been published
previously (Bai and Wong, 2005).
Candidate nuclear gene sequencing
Candidate nuclear genes (DRP1, MFF and FIS1) previously
implicated in mitochondrial ﬁssion were analysed by Sanger
sequencing of DNA extracted from blood from Patients 1
and 2.
Homozygosity mapping
Genome-wide SNP (single nucleotide polymorphism) array was
performed using Illumina HumanCytoSNP 12 in Patient 1,
Patient 2 and both parents to search for regions of homozy-
gosity by descent that might contain the mutated gene.
Whole exome sequencing and ﬁltering criteria
The whole exome was sequenced in Patients 1 and 2 using the
Illumina HiSeq 2000 platform. Sample preparation and enrich-
ment was performed according to Agilent’s SureSelect Protocol
Version 1.2. Concentration of each library was determined
using Agilent’s QPCR NGS Library Quantiﬁcation Kit
(G4880A). Samples were pooled prior to sequencing, with
each sample at a ﬁnal concentration of 10nM. Read ﬁles
(Fastq) were generated from the sequencing platform via
runs to an average 50 coverage on an in-house HiSeq
2000 system (Illumina). Raw fastq ﬁles were aligned to the
GRCh37 reference genome using novoalign version 2.08.03.
Duplicate reads were marked using Picard tools
MarkDuplicates. Calling was performed using the haplotype
caller module of GATK (https://www.broadinstitute.org/gatk,
version 3.1-1), creating gVCF formatted ﬁles for each
sample. The individual gVCF ﬁles for the exomes discussed
in this study, in combination with 3000 clinical exomes
Table 1 Molecular defects leading to disturbed mitochondrial dynamics
Genetic defect Mechanism Clinical features
DNM1L (DRP1) Impaired ﬁssion Fatal infantile encephalopathy (cardiomyopathy in a mouse model)
MFF (mitochondrial ﬁssion factor) Impaired ﬁssion Encephalopathy and neuropathy
MFN2 (mitofusin 2) Impaired fusion Charcot–Marie–Tooth disease type 2A (peripheral neuropathy, sometimes with
optic atrophy)
OPA1 Impaired fusion Autosomal dominant optic atrophy
PINK1 (PTEN-induced kinase 1) Impaired mitophagy Autosomal recessive juvenile parkinsonism
PARK2 (parkin) Impaired mitophagy Autosomal recessive juvenile parkinsonism
STAT2, a novel regulator of mitochondrial ﬁssion BRAIN 2015: Page 3 of 13 | 3
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 (UCL-exomes consortium), were combined into merged VCF
ﬁles for each chromosome containing on average 100 samples
each. The ﬁnal variant calling was performed using the GATK
GenotypeGVCFs module jointly for all samples (cases and con-
trols). Variant quality scores were then recalibrated according
to GATK best practices separately for indels and SNPs.
Resulting variants were annotated using ANNOVAR.
Candidate variants were ﬁltered based on function (non-syn-
onymous, presumed loss-of-function or splicing) and minor
allele frequency (50.5% minor allele frequency in our internal
control group, as well as the NHLBI exome sequencing data
set).
STAT2 lentiviral transduction and
silencing
STAT2 transduction
Lentiviral transduction of patient ﬁbroblasts with wild-type
STAT2 was performed to determine whether the mitochon-
drial ﬁssion defect could be rescued by exogenous wild-type
STAT2. The human STAT2 gene was cloned into the self-
inactivating HIV1-derived lentiviral vector plasmid as previ-
ously described (Demaison et al., 2002). The plasmid uses
the spleen focus-forming virus promoter to drive expression
of the STAT2. Expression was linked to enhanced green ﬂuor-
escent protein through an internal ribosomal entry site.
HEK293T cells were cultured in Dulbecco’s modiﬁed Eagle
medium (Invitrogen) supplemented with 10% foetal calf serum
(Sigma). These cells were seeded in T175 ﬂasks and grown
overnight to reach 80% conﬂuency. Each ﬂask was transfected
with 50mg vector plasmid, 17.5mg vesicular stomatitis virus
(VSV) envelope plasmid (pMDG), and 32.5mg gag/pol packa-
ging plasmid (pCMV8.74) using 2.5nM polyethylenimine.
Viral supernatant was harvested 48 and 72h after transfection,
ﬁltered at 0.22mm and concentrated by ultracentrifugation at
23000g for 2h at 4C using a Beckmann ultracentrifuge.
Virus particles were resuspended in Opti-Mem

and stored
at 80C. The number of viral infectious particles was calcu-
lated by ﬂow cytometry to measure GFP in HEK293T cells,
72h after transduction with serial dilutions of virus.
STAT2 silencing
Silencing the STAT2 gene in SHSY5Y cells was achieved by
transducing the cells with the pGIPZ shRNAmir vector, as
previously described (Fassone et al., 2010). Stably transduced
clones were selected in 1mg/ml puromycin (Gibco-Invitrogen).
STAT2 knockdown efﬁciency was tested by quantitative PCR
and immunoblot analyses.
Cellular analyses
Transcript expression
Total RNA was extracted from patient and control cells using
RNAqueous

-4PCR (ABI). For each sample, 1mg of total RNA
was reverse transcribed to cDNA using the high capacity RNA
to cDNA kit (ABI). Oligonucleotide primers for quantitative
real time PCR were designed using the universal probe library
(Roche Molecular Biochemicals), and synthesized at Sigma-
Genosys. Quantitative real time PCR was performed using
the Power SYBR

green mix (ABI) on a StepOne
TM
quantitative
PCR machine (ABI). The target genes analysed were DRP1,
MFN1, MFN2 and OPA1, with ACTB (encoding b-actin) as a
reference gene. Relative quantiﬁcation of gene expression in
patient samples was carried out against control 1 (C1).
Protein expression
For immunodetection of STAT2, DRP1 (and phospho-DRP1)
and the fusion proteins MFN1, MFN2 and OPA1, cell pellets
of ﬁbroblasts cultured in Dulbecco’s modiﬁed Eagle medium
containing GlutaMAX
TM
-I and 50mM glucose (Life
Technologies) were extracted on ice in PBS, 1.5% n-dodecyl-
b-D-maltoside. Equal concentrations of protein were denatured
in Laemmli sample Buffer and 10mM dithiotreitol, resolved
on 4–15% Mini-Protean

TGX Stain-Free
TM
gels with Precision
Plus Protein standards and blotted onto 0.2mm PVDF mem-
branes with a Trans-blot

Turbo
TM
Transfer System (all from
Bio-Rad). Blots were blocked in PBS, 10% skimmed milk
powder (Fluka) and incubated overnight with primary anti-
body. For the phospho-immunoblots, the primary antibodies
used were: rabbit anti-Phospho-DRP1 (Ser616), rabbit anti-
Phospho-DRP1 (Ser637), rabbit anti-DRP1 (D6C7), rabbit
anti-STAT2 (Sigma) and anti-phosphorylated STAT1 antibo-
dies (all from Cell Signaling). For western blots the primary
antibodies used were: anti-DRP1 (BD Transduction
Laboratories), anti-MFN1 (Abcam), anti-MFN2 (Abcam),
anti-OPA1 (BD Transduction Laboratories), anti-MTCO2
(Abcam), anti-TOM20 (Santa Cruz Biotechnology) and anti-
b-actin (Abcam). Blots were incubated with the appropriate
secondary antibody (polyclonal goat anti-mouse or anti-
rabbit IgG/HRP from Dako) and were developed for 5min
with Clarity
TM
Western ECL substrates (Bio-Rad) and visua-
lized on a ChemiDoc
TM
MP imager (Bio-Rad).
DRP1 localization
Cells were grown on glass chamber slides (Ibidi), ﬁxed with
paraformaldehyde and incubated with anti-DRP1 primary
antibody (Cell Signaling) overnight and anti-rabbit FITC con-
jugated secondary antibody (Sigma) for 1h. Nuclei were
stained with Hoechst and mitochondria were stained with
anti-TOM20 (Santa Cruz Biotechnology). Cells were viewed
under a Zeiss LSM 700 63 oil immersion objective using
appropriate ﬁlters.
Fluorescence-activated cell sorting for detection of
STAT1 phosphorylation
To detect STAT1 phosphorylation, native and transduced pa-
tient ﬁbroblasts were either left unstimulated or stimulated
with 10
5 units/ml of IFN (Stratech Scientiﬁc Limited). Cells
were then lysed, ﬁxed, washed and permeabilized before
adding 5ml anti-STAT1 phosphorylated tyrosine antibody
(BD Bioscience) as previously described (Walshe et al.,
2009). Ten thousand ﬁbroblasts were acquired and analysed
(FACSCalibur and CELLQest software 2.1.1, BD Biosciences).
The percentage change in phosphorylated cells was calculated
by subtracting the percentage of unstimulated cells from that
of the stimulated cells. Experiments were performed in tripli-
cate and expression levels were expressed as mean  standard
error (SE).
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 Apoptosis assay
Apoptosis was analysed in ﬁbroblasts derived from the STAT2
deﬁcient index patient (Patient 1) and compared to ﬁbroblasts
derived from healthy individuals. Cultured ﬁbroblasts were left
unstimulated or stimulated with 100 U/ml IFN (PBL
Interferon Source), 10mg/ml anti-fasL IgM (activating antibody
from Millipore) to crosslink the fasL receptor or phytohaem-
agglutinin (10mg/ml, BioStat). Five hours post stimulation,
cells were stained with Annexin V (Life Technologies) and
7AAD (BD Biosciences). Ten thousand cells were acquired
on a FACSCalibur and analysed using CellQuest Pro (BD
Biosciences) and the percentage of apoptotic cells deﬁned as
annexin V+7AAD+.
Results
Clinical ﬁndings and laboratory
analyses
The siblings Patients 1 and 2 presented with severe neuro-
logical deterioration following live attenuated viral immun-
ization, and also had evidence of immune deﬁciency. The
multisystem nature of their disease, together with mildly
elevated plasma and CSF lactate levels in Patient 1
(Supplementary Table 1), led to clinical suspicion of a mito-
chondrial disorder. The elevated CSF neopterin levels
observed in Patients 1 and 2 (Supplementary Table 1)
were also compatible with an underlying mitochondrial
disorder (Hasselmann et al., 2010). Consequently open
muscle biopsies were performed in both siblings.
Spectrophotometric analysis of mitochondrial respiratory
chain enzyme activities (OXPHOS complexes I–IV) was
normal in skeletal muscle from Patients 1 and 2
(Supplementary Table 1) but in-gel activity of ATP synthase
(complex V) was reduced on blue-native gel electrophoresis,
particularly in Patient 1 who was clinically more severely
affected (data not shown).
Histological analyses
Light microscopy of skeletal muscle was unremarkable but
electron microscopy of muscle and ﬁbroblasts from both
children revealed abnormally long mitochondria, between
8–10mm in length (Fig. 1A), suggesting defective mitochon-
drial ﬁssion.
Genetic analyses
Homozygosity mapping and candidate gene analysis
Genome-wide SNP array revealed several 1Mb regions of
homozygosity shared by the siblings, and an extended
region of homozygosity (10.6Mb) on chromosome 12 (pos-
ition: 52648837–63282047). Sanger sequencing excluded
mtDNA mutations and mutations in candidate genes
known or predicted to cause defective mitochondrial ﬁssion
(DRP1, MFF and FIS1)( Waterham et al., 2007;
Shamseldin et al., 2012; Shen et al., 2014). Absolute
quantiﬁcation of mtDNA copy number per cell showed a
2-fold increase in Patient 1 compared to ﬁve paediatric
controls [increased from a mean  standard deviation
(SD) of 658  136 in controls to 1310 in Patient 1].
Whole exome analysis
Whole exome sequencing did not demonstrate any
pathogenic mutations in known or putative mitochon-
drial disease genes in these siblings, but did reveal a
novel homozygous stop-gain mutation c.1836C4A
(p.Cys612Ter) in STAT2, located within the region of ex-
tended homozygosity on chromosome 12.
Molecular and functional characterization of
mutated STAT2
The homozygous c.1836C4A (p.Cys612Ter) mutation,
l o c a t e dw i t h i nt h eS H 2d o m a i no fS T A T 2w h i c hi sc r i t i c a l
for transcriptional function, was conﬁrmed by Sanger sequen-
cing and shown to be heterozygous in both parents (Fig. 1B).
STAT2 lentiviral transduction and
silencing
STAT2 transduction
Confocal microscopy demonstrated dense, elongated mito-
chondria in patient ﬁbroblasts compared to controls in
80% conﬂuent cell cultures (Fig. 2) We found that mito-
chondria from a clinically similar but unrelated patient
(Patient 3), previously reported with a homozygous splice
mutation in STAT2 (c.381 + 5G4C), were also elongated
and tubular (Fig. 2), conﬁrming the association between
STAT2 deﬁciency and mitochondrial elongation.
Furthermore patient cells were transduced with wild-type
STAT2 and the delivery of the correct version of STAT2
was conﬁrmed by green ﬂuorescent microscopy (Fig. 3A).
Analysing the mitochondrial length using TMRM (Fig. 2)
and quantitative methods such as ImageJ (Fig. 3B)
and IMARIS X64 software (Fig. 3C) revealed an average
3-fold decrease in mitochondrial length in patient ﬁbro-
blasts compared to controls following transduction with
wild-type STAT2.
STAT2 silencing
To conﬁrm the speciﬁc role of STAT2 as a determinant of
mitochondrial structure, SHSY5Y cells were transduced
with siRNA targeting STAT2. Quantitative analysis
showed a 4-fold increase in mitochondrial length in
STAT2-knockout SHSY5Y cells compared to wild-type
(Fig. 2B and C).
Cellular analyses
Transcript expression
We observed no difference in expression of genes encoding
ﬁssion (DNM1L, also known as DRP1) and fusion
STAT2, a novel regulator of mitochondrial ﬁssion BRAIN 2015: Page 5 of 13 | 5
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 (MFN1, MFN2 and OPA1) proteins between patient and
control ﬁbroblasts (Fig. 4A).
Protein expression
Western blot analysis revealed that STAT2 protein was un-
detectable in ﬁbroblasts from all three patients Patients 1–3
(Fig. 5A), conﬁrming nonsense mediated decay. We exam-
ined the effects of STAT2 deﬁciency on proteins involved
in mitochondrial ﬁssion and fusion. Steady-state levels of
DRP1 were similar in cytoplasmic protein extracts of cul-
tured ﬁbroblasts from Patient 1 and Patient 3, compared to
six control subjects. However, the outer and inner mitochon-
drial membrane fusion proteins MFN1, MFN2 and OPA1
were increased in Patient 1 and Patient 3 compared to the six
control ﬁbroblasts (Fig. 4B). Further analyses demonstrated
that the steady-state levels of mitochondrial cytochrome c
oxidase subunit II (MT-CO2) and the translocase of outer
mitochondrial membrane 20 (TOM20, encoded by
TOMM20) were similarly increased in the patients (Fig. 4B).
DRP1 localization
For DRP1 to exert its effects on initiation of mitochondrial
ﬁssion, it ﬁrst needs to be localized to the mitochondria.
Using confocal microscopy, we examined DRP1 localiza-
tion in Patient 1 and control ﬁbroblasts, and found DRP1
to be co-localized with the outer mitochondrial membrane
protein TOM20 in both patient and control ﬁbroblasts.
Thus a deﬁciency of STAT2 protein does not appear to
affect DRP1 localization to the mitochondria (Fig. 4C).
DRP1 phosphorylation
To further investigate the underlying cause of the long mito-
chondria, we measured activation of DRP1, the main ﬁssion
factor in human mitochondria. As DRP1 levels and localiza-
tion were normal in patient cells, we hypothesized that
DRP1 might be inactive in patient cells and therefore
unable to complete the ﬁssion process. DRP1 activity is
dually regulated by phosphorylation at two key serine resi-
dues. Post-translational modiﬁcation by phosphorylation at
Figure 1 Analysis of muscle and cultured skin ﬁbroblasts. (A) Representative electron micrographs of muscle (longitudinal sections, top)
and ﬁbroblasts (bottom) in patients and controls. Red arrows show mitochondria. (B) Top: Electropherograms showing Sanger sequence con-
ﬁrmation of novel homozygous stop gain mutation c.1836C4A (p.Cys612Ter) in STAT2 identiﬁed by whole exome sequencing in Patients 1 and 2.
Parents are both heterozygous for the mutation. Bottom: The mutation leads to a stop-gain at amino acid position 612 of the highly conserved SH2
domain of STAT2 protein. P represents phosphorylation sites on STAT2.
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 serine residue 616 (P-DRP1
S616) is known to activate DRP1,
whereas phosphorylation at serine 637 (P-DRP1
S637)i sa s s o -
ciated with the inactive state of the GTPase. Reduced P-
DRP1
S616 and increased P-DRP1
S637 was observed in all
three patients compared to controls (Fig. 5), indicating that
DRP1 is inactive in STAT2 deﬁciency. Introduction of wild-
type STAT2 into patient ﬁbroblasts using lentiviral transduc-
tion reversed the phenotypes; we observed increased P-
DRP1
S616, decreased P-DRP1
S637 and shorter mitochondria,
reﬂecting a state of increased ﬁssion. Conversely, knock
down of STAT2 in SHSY5Y cells led to increased P-
DRP1
S637and reduced P-DRP1
S616 (Fig. 5)a n de x t r e m e l y
elongated mitochondria (Fig. 2B), recapitulating the pheno-
type in STAT2-deﬁcient ﬁbroblasts.
STAT1 phosphorylation detected by ﬂuorescence-
activated cell sorting
As well as STAT2, phosphorylation of another STAT pro-
tein called STAT1, was also disrupted in Patient 1 and
Patient 2 ﬁbroblasts compared to controls and recovered
signiﬁcantly after transducing the cells with wild-type
STAT2 (Fig. 6A and B), conﬁrming disturbance of the
IFN pathway and explaining the susceptibility to viral in-
fection in these patients.
Apoptosis assay
ImageJ analysis of TMRM stained ﬁbroblasts revealed
reduced mitochondrial membrane potential in all three pa-
tient ﬁbroblasts Patients 1–3 (Fig. 6C). We therefore inves-
tigated apoptosis in Patient 1 cells compared to healthy
controls. Induction with phytohaemagglutinin and anti-
fasL both induced comparable apoptosis in patient and
control cells. However, the STAT2 deﬁcient cells failed to
undergo apoptosis in response to IFN (Fig. 6D). Both
phytohaemagglutinin and anti-fasL induction of apoptosis
resulted in the activation of caspase 3. These results indi-
cate that there is not an inherent apoptotic defect in these
cells but that IFN induced apoptosis is severely impaired,
Figure 2 Mitochondrial length analysis using TMRM staining and confocal microscopy. (A) TMRM labelled mitochondria in Patients
1–3 ﬁbroblasts (top), transduced with wild-type STAT2 (middle), and DRP1
, STAT1
 and healthy control (HC) cells (bottom); all cells at 70%
conﬂuency. Minus sign represents autosomal dominant mutation. (B) TMRM labelled mitochondria in SHSY5Y cells, wild-type (left) and STAT2
knockout (right). (C) ImageJ quantitation of mitochondrial perimeter length in ﬁbroblasts (top) and SHSY5Y cells (bottom). **P50.005.
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 consistent with previous observations in STAT2 knock-
down cell models (Romero-Weaver et al., 2010).
Discussion
We have found that STAT2, a component of the JAK-
STAT cytokine signalling pathway, is a novel regulator of
mitochondrial ﬁssion. This provides new insight into how
the cell may orchestrate mitochondrial morphology and dy-
namics in concert with other cellular compartments.
Modulation of mitochondrial shape can be detrimental to
organelle function and can lead to a distinct shift in cell
viability with unregulated ﬁssion reported in neurodegen-
erative disorders such as Alzheimer’s, Huntington’s and
Parkinson’s diseases (Dagda et al., 2009; Wang et al.,
2009; Kim et al., 2010).
DRP1 is the master regulator of mitochondrial ﬁssion,
though how it is ultimately recruited to the mitochondrial
outer membrane remains largely unknown (Palmer et al.,
2011; Loso ´n et al., 2013). Complicating the issue further is
the fact that DRP1 can undergo numerous post-
translational modiﬁcations by the action of various proteins
at different stages of the cell cycle. In this report, studies of
mitochondrial morphology in three patients from two un-
related pedigrees with STAT2 mutations revealed an elon-
gated mitochondrial network. It appears that these patients
harbour decreased levels of DRP1 phosphorylated at serine
616 (P-DRP1
S616) and increased levels of DRP1 phosphory-
lated at serine 637 (P-DRP1
S637). Both post-translational
modiﬁcations render DRP1 largely inactive in the cytosol,
unable to polymerise into higher order structures and as-
semble into the ﬁssion apparatus on the mitochondrial
outer membrane—thus causing a block in the ﬁssion
Figure 3 Image analysis of mitochondria in transduced patient and control ﬁbroblasts. (A) Conﬁrmation of lentiviral transduction
in patient ﬁbroblasts using GFP tag. Patient ﬁbroblasts transduced with STAT2, stained with TMRM (left) and GFP expression upon reintroduc-
tion of STAT2 (right). Scale bar = 20mm. (B) TMRM stained mitochondria in STAT2 transduced patient and control ﬁbroblasts. Mito-Morphology
Macro was installed on ImageJ, which measures mitochondrial interconnectivity and elongation from epiﬂuorescence micrographs of cells
stained for mitochondria. The perimeter length of the selected mitochondria is then measured using the software. Scale bar = 50mm.
(C) Three-dimensional representations of mitochondria in Patient 1 ﬁbroblasts before (top) and after (middle) transduction with STAT2,
and control ﬁbroblasts (bottom). Confocal z-stack images of mitochondria stained with TMRM were reconstructed using IMARIS X64 soft-
ware (version 7.6.3, Bitplane) to give 3D representations of the mitochondria present in each cell. Single connected mitochondria depicted as
yellow.
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 process (Taguchi et al., 2007; Chang and Blackstone, 2010;
Gomes et al., 2011). Deducing what is a block in ﬁssion
and what is stress induced hyperfusion is at times difﬁcult;
however, hyperfusion is most commonly observed as an
acute response to stress and is a transient state before mito-
chondrial fragmentation (Gomes et al., 2011).
We observed normal steady state levels of DRP1 and
increased protein levels of the fusion proteins MFN1,
MFN2 and OPA1 and also other mitochondrial proteins
(MTCO2 and TOM20) compared to controls. This sug-
gests that the relative mitochondrial hyperfusion, as a
result of defective ﬁssion following DRP1 inactivation in
STAT2 deﬁciency, leads to an increase in mitochondrial
mass and results in raised levels of mitochondrial proteins,
including MFN1, MFN2 and OPA1, but does not affect the
levels of cytosolic proteins, such as DRP1. The increase in
mitochondrial mass is further corroborated by the doubling
in mtDNA copy number in cultured ﬁbroblasts from
Patient 1 (data not shown). Given the reduction in en-
dogenous levels of P-DRP1
S616 in these patients with
STAT2 mutations, it would seem that a modulation in
the activity of DRP1 is directly responsible for the mito-
chondrial phenotype and results in defective ﬁssion.
Intercurrent infection frequently triggers severe decom-
pensation in patients with mitochondrial disease. It has
been assumed that the underlying energy defect limits
the ability of the patient to cope with the added meta-
bolic stress of infection. However, more recently, we have
observed in our clinical practice that very speciﬁc infec-
tions can trigger fatal outcomes in patients who were not
previously known to have mitochondrial disease prior to
the viral illness. For example, we demonstrated that a
previously well infant with overwhelming cardiomyopathy
following respiratory syncytial virus infection had muta-
tions in the NDUFAF1 gene encoding an assembly
factor of complex I, a key enzyme of OXPHOS
Figure 4 Transcript and protein expression of ﬁssion and fusion proteins and DRP1 localization. (A) Quantitative PCR analysis of
DRP1, MFN1, MFN2 and OPA1 in three controls (C1–C3) and two patients (Patients 1 and 3). The samples were normalized to C1 and ACTB
encoding b-actin was used as an endogenous control (n=3). (B) Western blot analyses of 14mg protein extracted with 1.5% n-dodecyl-b-D-
maltoside from control (C1–6) and patient (Patients 1 and 3) ﬁbroblast cultures. Blots were probed with antibodies raised against DRP1, MFN1,
MFN2, OPA1, MTCO2 and TOM20 as indicated. An antibody raised against b-actin served as loading control. (C) DRP1 localization was carried
out by labelling the mitochondria with TOM20, DRP1 with FITC conjugated secondary antibody and nuclei with Hoechst and visualized under a
confocal microscope. Overlaid images show DRP1 co-localization with TOM20 on the mitochondria.
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 (Fassone et al., 2011). We also found mutations in an-
other complex I assembly factor in another previously
well infant who died of severe cardiomyopathy following
parainﬂuenza infection (unpublished data). STAT2-knock-
out mice have severe susceptibility to viral infection, and
STAT2 is a binding target for measles, a possible culprit
in these patients (Park et al., 2000; Rarnachandran et al.,
2008; Alazawi et al., 2013).
In view of the endosymbiotic hypothesis (which proposes
that mitochondria originate from bacteria which were en-
gulfed by and subsequently developed an endosymbiotic
relationship with the host eukaryotic cell (Margulis,
Figure 5 DRP1 phosphorylation in patients and controls. (A) Protein samples (20mg) from ﬁbroblasts and SHSY5Y cells were separated
by sodium dodecyl sulphate polyacrylamide gel electrophoresis and immunoblotted with the indicated antibodies. STAT2 protein was not
detectable in the three patients (P1–3) conﬁrming nonsense mediated decay; STAT2 levels were restored after lentiviral transduction with STAT2
(top). Total DRP1 protein levels remained constant throughout (second panel from top), but DRP1 phosphorylation at serine 616 was very low in
STAT2 deﬁcient cells and increased after lentiviral transduction with wild-type STAT2 (third panel), whilst phosphorylation at serine 637 reduced
after STAT2 transduction (fourth panel). Actin was used as a loading control (bottom). (B) Quantitative analysis of phosphorylation at serines 616
and 637 of DRP1 in STAT2 transduced patient and control ﬁbroblasts (left) and SHSY5Y wild-type and STAT2 knockout cells (right). Data were
normalized to the total level of DRP1 and represent the mean  SD of three independent experiments. *P50.05, **P50.005.
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 1975), it is not surprising that components of the innate
immune system may also interact with, and perhaps even
regulate, mitochondria. The data from this study suggest an
unexpected link between innate immunity and mitochon-
drial function and suggest a potential new avenue for de-
veloping pharmacological strategies to treat mitochondrial
diseases, for which virtually no effective curative treatments
exist at present (Kanabus et al., 2014).
Seven known mammalian STATs have been reported to be
transcription factors with diverse biological functions, includ-
ing immune regulation and development (Meier and Larner,
2014). Recently, non-canonical STAT functions have
emerged, suggesting they play fundamental roles in cellular
homeostasis (Meier and Larner, 2014). STAT3, the ﬁrst to
be found in mitochondria, has been implicated in the function
of OXPHOS complexes I and II, suggesting that STAT3 is
required for optimal energy production (Wegrzyn et al.,
2009). Basal pools of STAT1 and STAT2 have recently also
been identiﬁed within mitochondria, and have been postulated
to down regulate mitochondrial transcription (Goswami et al.,
2013; Lartigue and Faustin, 2013), possibly to co-ordinate the
immune response and energy production. This is particularly
interesting in light of a recent report that DRP1 may control
T-cell activation at the immune synapse (Baixauli et al.,
2011). Previously cyclin B1-cyclin-dependent kinase and
cAMP-dependent protein kinase A have been demonstrated
to phosphorylate DRP1 on Ser616 and Ser637 respectively
(Archer, 2013). We now suggest that STAT2 is an additional
phosphorylase capable of phosphorylating DRP1 on Ser616.
In summary, STATs have increasingly recognized roles in
mitochondrial function, and we have demonstrated that
STAT2 is a novel regulator of mitochondrial ﬁssion
(Fig. 7). Manipulation of the JAK-STAT pathway may rep-
resent a novel therapeutic strategy for mitochondrial dis-
eases, by ﬁne-tuning the balance of mitochondrial ﬁssion
and fusion.
Figure 6 STAT1 phosphorylation before and after stimulation with IFNa, membrane potential and apoptosis levels.
(A) Representative FACS dot blot graph showing phosphorylated STAT1 in STAT2 transduced cells compared to non-transduced STAT2 deﬁcient
cells after stimulation (results for Patient 3 shown). (B) The percentage change in phosphorylated cells was calculated from the data from
A [patient cells, transduced cells and SHSY5 wild-type (WT) and STAT2 knockout (KO) cells]. Data represents the mean  SD (n=3). *P50.05,
**P50.005 (C) Membrane potential analysis in control and patient cells using TMRM staining. The mean ﬂuorescence intensity was analysed via
confocal microscopy and Image J (n=3;427 cells analysed for each n,  SEM) *P50.05, **P50.005. (D) Apoptosis was analysed in ﬁbroblasts
derived from the STAT2 deﬁcient patient (Patient 1) and compared to ﬁbroblasts derived from healthy individuals. Cultured ﬁbroblasts were left
unstimulated or stimulated with 100 U/ml IFN,1 0mg/ml anti-fasL IgM or phytohaemagglutinin. Cells were analysed using CellQuest Pro and the
percentage of apoptotic cells deﬁned as annexin V+7AAD+.
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